Page 16 - HFA_Dateline_2019_Q1_Spring_SpecialEdition

Current Products | Factor IX

IX Recombinant Clotting Factor

Manufacturer Product Type Half Life
24 hours
Aptevo IXINITY Recombinant Clotting Factor
Therapeutics

Bioverativ Alprolix Recombinant Clotting Factor 86.52 Hrs (37.2%) in adults
Pediatric:
CSL Behring Idelvion Recombinant Clotting Factor 12 to 17 years: 80 hours (15%)
6 to 11 years: 72 hours (23%)
Novo Nordisk REBINYN Recombinant Clotting Factor 2 to 5 years: 68 hours (24%)

After single dose of 50 IU/kg:
Adults: 104 hours;
Adolescents (12 to <18 years): 87 hours (mean);
Children: (0 to <6 years): 90 hours (mean);
and (6 to <12 years): 93 hours (mean)

Single Dose
• ≤ 6 years- 69.6 hours
• 7-12 years old - 76.3 hours
• 13-17 years old - 89.4 hours
• ≥ 18 years old - 83.0 hours

Steady State
• 13-17 years old - 103.1 hours
• ≥ 18 years old - 114.9 hours

Pfizer BeneFIX Recombinant Clotting Factor 18.8 ± 5.4 hours (range 11 to 36 hours)d,e

Takeda Rixubis Recombinant Clotting Factor ≥12 years= 25.7 ± 1.5 hrs; 6 -<12 years= 23.2 ±
1.6 hrs; <6 years= 27.7 ± 2.7 hrs
(formerly Shire)
Half Life
IX Plasma-derived Clotting Factor 22.6 to 25.3 hours (mean)

Manufacturer Product Type

CSL Behring Mononine Plasma-Derived Clotting Factor
Grifols Alphanine SD Plasma-Derived Clotting Factor

Grifols Profilnine SD Plasma-Derived Clotting Factor

16 Dateline Federation | Special Issue 2018-19